Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05073315 · ClinicalTrials.gov registry record · Phase 3
A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 425
- Enrollment target
NCT05073315 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 425 participants.
The verdict
NCT05073315, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 425 participants
- Enrollment target
Study Summary
Study to evaluate pharmacokinetics, efficacy, safety and immunogenicity of multiple switches between Humira® and ABP 501 (new high concentration formulation) compared with continued use of Humira® in participants with moderate to severe plaque psoriasis. This multi-center study is composed of two periods: A lead-in period of treatment with Humira® followed by a randomized two parallel arm period.
Interventions
- DRUG Adalimumab
- DRUG ABP 501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 425 participants |
| Start Date | 2021-10-04 |
| Est. Completion | 2022-12-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05073315
The ClinicalTrials.gov registry entry for NCT05073315 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 425 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Adalimumab is the first listed.
NCT05073315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05073315 about?
NCT05073315 is a clinical study titled "A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis". Study to evaluate pharmacokinetics, efficacy, safety and immunogenicity of multiple switches between Humira® and ABP 501 (new high concentration formulation) compared with continued use of Humira® in participants with moderate to severe plaque psoriasis. This multi-center study is composed of two pe...
What is the current status of trial NCT05073315?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 425 participants. The study started on 2021-10-04. Estimated completion is 2022-12-19.
What interventions are being tested in trial NCT05073315?
The interventions under investigation include: Adalimumab (DRUG), ABP 501 (DRUG).
Who is sponsoring clinical trial NCT05073315?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.